79418-76-1

Upstream product

• 71144-36-0 2-fluoro-4,5-dihydroxy-benzaldehyde 
• 7664-93-9 sulfuric acid 
• 71924-62-4 2-fluoro-4,5-dimethoxybenzaldehyde 

Downstream Products

• 775350-82-8 (4-chloro-phenyl)-(5-cyclopentyloxy-2-fluoro-4-methoxy-phenyl)-methanol 
• 166742-00-3 3-cyclopentyloxy-6-fluoro-4-methoxybenzaldehyde 
• 934162-88-6 4-Fluoro-5-{[2-(4-hydroxyphenyl)ethylamino]-methyl]-2-methoxy-phenol 
• 1335242-21-1 6-fluoro-3-hydroxy-4-methoxystyrene 
• 1335242-39-1 (E)-6-fluoro-4-methoxy-2',3,5'-trihydroxystilbene 

Relevant academic research and scientific papers

PENICILLIN-BINDING PROTEIN INHIBITORS

Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds describ

PENICILLIN-BINDING PROTEIN INHIBITORS

Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds describ

Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine

Compounds as PDE IV and TNF inhibitors

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

Structure-activity relationship studies directed toward improving the potency and metabolic stability of CDP-840 (3) resulted in the discovery of L-791,943 (11n) as a potent (HWB TNF-alpha = 0.67 microM) and orally active phosphodiesterase type 4 (PDE4) inhibitor. This compound, which bears a stable bis-difluoromethoxy catechol and a pendant hexafluorocarbinol, exhibited a long half-life in rat and in squirrel monkey. It is well tolerated in ferret with an emetic threshold greater than 30 mg/kg (po) and was found to be active in the ovalbumin-induced bronchoconstriction model in guinea pig and in the ascaris-induced bronchoconstriction models in sheep and squirrel monkey.